Form 5 - Annual statement of changes in beneficial ownership of securities:
SEC Accession No. 0001437749-23-000585
Filing Date
2023-01-05
Accepted
2023-01-05 19:31:11
Documents
1
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 5 rdgdoc.html 5  
1 FORM 5 rdgdoc.xml 5 4753
  Complete submission text file 0001437749-23-000585.txt   6259
Mailing Address 140 INTRACOASTAL POINTE DRIVE SUITE 404 JUPITER FL 33477
Business Address 140 INTRACOASTAL POINTE DRIVE SUITE 404 JUPITER FL 33477 561-743-8333
DYADIC INTERNATIONAL INC (Issuer) CIK: 0001213809 (see all company filings)

EIN.: 450486747 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O KERYX BIOPHARMACEUTICALS 750 LEXINGTON AVENUE NEW YORK X1 10022
Business Address
Kaye Jack (Reporting) CIK: 0001376099 (see all company filings)

Type: 5 | Act: 34 | File No.: 001-32513 | Film No.: 23513163